Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Roboz

Showing results (121-130 of 276) with videos related to

Pageof 28
Sort By:
Leukemia & Lymphoma|May 6, 2014
Phase I trial of SAR103168, a novel multi-kinase inhibitor, in patients with refractory/relapsed acute leukemia or high-risk myelodysplastic syndromeGail J Roboz, H Jean Khoury, Elias Jabbour, et al.
The Journal of Molecular Diagnostics : JMD|May 20, 2017
Minimal Residual Disease Monitoring of Acute Myeloid Leukemia by Massively Multiplex Digital PCR in Patients with NPM1 MutationsNuria Mencia-Trinchant, Yang Hu, Maria Antonina Alas, et al.
Leukemia & Lymphoma|December 17, 2002
Efficacy and safety of gemtuzumab ozogamicin in patients with poor-prognosis acute myeloid leukemiaG J Roboz, M A Knovich, R L Bayer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2021
Project 2025: Proposals for the Continued Success of Drug Development in Acute Myeloid LeukemiaDaniel A Pollyea, John Barrett, Courtney D DiNardo, et al.
Leukemia & Lymphoma|October 25, 2022
Immunogenicity of COVID-19 mRNA vaccines in patients with acute myeloid leukemia and myelodysplastic syndromeDavid C Helfgott, Sabrina Racine-Brzostek, Kelsey J Short, et al.
Leukemia|April 18, 2006
Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndromeG J Roboz, F J Giles, A F List, et al.
Leukemia & Lymphoma|June 27, 2009
Complete remissions observed in acute myeloid leukemia following prolonged exposure to lintuzumab: a phase 1 trialAzra Raza, Joseph G Jurcic, Gail J Roboz, et al.
Leukemia & Lymphoma|February 15, 2021
A dose escalation study of RO6870810/TEN-10 in patients with acute myeloid leukemia and myelodysplastic syndromeGail J Roboz, Pinkal Desai, Sangmin Lee, et al.
Cancer|October 6, 2018
Low clinical trial accrual of patients with myelodysplastic syndromes: Causes and potential solutionsDavid P Steensma, Andrew M Brunner, Amy E DeZern, et al.
Leukemia Research|June 15, 2007
PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasiaFrancis J Giles, Alan F List, Michael Carroll, et al.
Pageof 28

Showing results (121-130 of 276) with videos related to

Sort By:
Pageof 28
Leukemia & Lymphoma|May 6, 2014
Phase I trial of SAR103168, a novel multi-kinase inhibitor, in patients with refractory/relapsed acute leukemia or high-risk myelodysplastic syndromeGail J Roboz, H Jean Khoury, Elias Jabbour, et al.
The Journal of Molecular Diagnostics : JMD|May 20, 2017
Minimal Residual Disease Monitoring of Acute Myeloid Leukemia by Massively Multiplex Digital PCR in Patients with NPM1 MutationsNuria Mencia-Trinchant, Yang Hu, Maria Antonina Alas, et al.
Leukemia & Lymphoma|December 17, 2002
Efficacy and safety of gemtuzumab ozogamicin in patients with poor-prognosis acute myeloid leukemiaG J Roboz, M A Knovich, R L Bayer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2021
Project 2025: Proposals for the Continued Success of Drug Development in Acute Myeloid LeukemiaDaniel A Pollyea, John Barrett, Courtney D DiNardo, et al.
Leukemia & Lymphoma|October 25, 2022
Immunogenicity of COVID-19 mRNA vaccines in patients with acute myeloid leukemia and myelodysplastic syndromeDavid C Helfgott, Sabrina Racine-Brzostek, Kelsey J Short, et al.
Leukemia|April 18, 2006
Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndromeG J Roboz, F J Giles, A F List, et al.
Leukemia & Lymphoma|June 27, 2009
Complete remissions observed in acute myeloid leukemia following prolonged exposure to lintuzumab: a phase 1 trialAzra Raza, Joseph G Jurcic, Gail J Roboz, et al.
Leukemia & Lymphoma|February 15, 2021
A dose escalation study of RO6870810/TEN-10 in patients with acute myeloid leukemia and myelodysplastic syndromeGail J Roboz, Pinkal Desai, Sangmin Lee, et al.
Cancer|October 6, 2018
Low clinical trial accrual of patients with myelodysplastic syndromes: Causes and potential solutionsDavid P Steensma, Andrew M Brunner, Amy E DeZern, et al.
Leukemia Research|June 15, 2007
PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasiaFrancis J Giles, Alan F List, Michael Carroll, et al.
Pageof 28